Literature DB >> 1451727

Population pharmacokinetic parameters for Bayesian monitoring of amikacin therapy in intensive care unit patients.

J Debord1, J C Voultoury, G Lachatre, C Gay, J P Favereau, R Gay.   

Abstract

The pharmacokinetics of amikacin has been studied in 40 intensive care unit patients using the bayesian estimation method implemented in the USC PC PACK program of Jelliffe. The volume of the central compartment was significantly higher in these patients than in the reference population, while other pharmacokinetic parameters did not differ significantly from the reference values. The population values may be employed, in addition to those supplied with the software, to adapt dosage regimens of amikacin in ICU patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1451727     DOI: 10.1007/bf02220623

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

Review 1.  Individualising gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring strategies.

Authors:  R W Jelliffe; T Iglesias; A K Hurst; K A Foo; J Rodriguez
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

2.  Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients.

Authors:  R L Reed; A H Wu; P Miller-Crotchett; J Crotchett; R P Fischer
Journal:  J Trauma       Date:  1989-11

3.  Bayesian forecasting of serum gentamicin concentrations in intensive care patients.

Authors:  K A Rodvold; R D Pryka; P G Kuehl; R A Blum; P Donahue
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

4.  [Comparative pharmacokinetics of amikacin after intravenous, intramuscular and subcutaneous administration].

Authors:  B Leng; M C Saux; J Latrille
Journal:  Nouv Presse Med       Date:  1979-10-31

5.  Gentamicin volume of distribution in critically ill septic patients.

Authors:  C Triginer; I Izquierdo; R Fernández; J Rello; J Torrent; S Benito; A Net
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 6.  An updated comparison of drug dosing methods. Part III: Aminoglycoside antibiotics.

Authors:  S M Erdman; K A Rodvold; R D Pryka
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

  6 in total
  3 in total

1.  Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime.

Authors:  A D Kashuba; C H Ballow; A Forrest
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

2.  Influence of clinical diagnosis in the population pharmacokinetics of amikacin in intensive care unit patients.

Authors:  S Romano; M Del Mar Fdez de Gatta; V Calvo; E Mendez; A Domínguez-Gil; J M Lanao
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

3.  Amikacin population pharmacokinetics in critically ill Kuwaiti patients.

Authors:  Kamal M Matar; Yousef Al-lanqawi; Kefaya Abdul-Malek; Roger Jelliffe
Journal:  Biomed Res Int       Date:  2013-01-30       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.